DA Davidson Starts Nike (NKE) at Buy; Revenue Growth is Running Strong
Get Alerts NKE Hot Sheet
Price: $40.73 --0%
Rating Summary:
26 Buy, 28 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 17
Rating Summary:
26 Buy, 28 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 6 | Down: 11 | New: 17
Join SI Premium – FREE
DA Davidson initiates coverage on Nike (NYSE: NKE) with a Buy. PT $129.00.
Analyst, Andrew Burns, said, "Given NIKE’s leadership position, recent fundamental strength, track record of creating shareholder value, and long-term growth potential, we view its premium valuation as justified. We see share appreciation with earnings growth as the company executes on its global growth strategy."
"We are introducing F3Q12 revenue and EPS estimates of $5.821 billion and $1.19. Our FY12 and FY13 estimates are $24.232 billion and $5.01 and $26.938 billion and $6.04, respectively. Our calendar year 2013 EPS estimate is $6.46."
For an analyst ratings summary and ratings history on Nike click here. For more ratings news on Nike click here.
Shares of Nike closed at $110.73 yesterday.
Analyst, Andrew Burns, said, "Given NIKE’s leadership position, recent fundamental strength, track record of creating shareholder value, and long-term growth potential, we view its premium valuation as justified. We see share appreciation with earnings growth as the company executes on its global growth strategy."
"We are introducing F3Q12 revenue and EPS estimates of $5.821 billion and $1.19. Our FY12 and FY13 estimates are $24.232 billion and $5.01 and $26.938 billion and $6.04, respectively. Our calendar year 2013 EPS estimate is $6.46."
For an analyst ratings summary and ratings history on Nike click here. For more ratings news on Nike click here.
Shares of Nike closed at $110.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
- Celcuity (CELC) Reiterates at Market Outperform by Citizens Ahead of Upcoming Launch
- Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c
Create E-mail Alert Related Categories
New CoverageRelated Entities
D.A. Davidson, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share